Evidence map›Paper›PMID 34609601›Full record

ArticleJournal of neurology2022

SARS-CoV-2 antibody seroprevalence in a large neuroimmunological patient cohort.

Katharina Eisenhut, Stefan Buchka, Peter Eichhorn, Harald Meier, Fady Albashiti, Ulrich Mansmann, Miriam Schlüter, Joachim Havla, Tania Kümpfel

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katharina EisenhutInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Stefan BuchkaInstitute of Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, LMU Munich, Munich, Germany.
Peter EichhornInstitute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany.
Harald MeierData Integration for Future Medicine (DIFUTURE) Consortium, LMU Munich, Munich, Germany.
Fady AlbashitiData Integration for Future Medicine (DIFUTURE) Consortium, LMU Munich, Munich, Germany.
Ulrich MansmannInstitute of Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, LMU Munich, Munich, Germany.
Miriam SchlüterInstitute of Clinical Neuroimmunology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Joachim Havla *Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Tania Kümpfel *Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. tania.kuempfel@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-7509-5268

Funding

bundesministerium für bildung und forschung 01ZZ1603[A-D]bundesministerium für bildung und forschung 01ZZ1804[A-H] (DIFUTURE)
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCohort StudiesHumansSeroepidemiologic StudiesAntibodies, Viral

Identifiers

PMID34609601
PMCPMC8491170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.